Approvals & Mergers: Inside Enzyvant with Bill Symonds, Pharm.D.
Business Of Biotech
00:00
Enzavant's Approval of a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athena
We're going to talk about the company's approval of rithymic, a one-time regenerative tissue-based therapy for pediatric congenital Athena. And we'll learn where the company is taking its programs in pulmonary arterial hypertension, idiopathic pulmonary fibrosis, transplant-associated bronchiolitis and oblitteran syndrome. Dr. Simmons: "I appreciate the opportunity and look forward to the conversation"
Transcript
Play full episode
